Antibodies to vascular endothelial growth factor 2 (VEGF-2)

Details Antibodies to vascular endothelial growth factor 2 (VEGF-2) Antibodies to vascular endothelial growth factor 2 (VEGF-2)

2008-07-22

2008-07-22

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S145100

Reexamination Certificate

active

07402312

ABSTRACT:
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention also relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7223724 (2007-05-01), Alderson et al.
patent: 7227005 (2007-06-01), Hu et al.
patent: 710696 (1999-09-01), None
patent: 0 476983 (1992-03-01), None
patent: 0-476983 (1992-03-01), None
patent: 0-506477 (1992-09-01), None
patent: WO-92/14748 (1992-09-01), None
patent: WO-95/19985 (1995-07-01), None
patent: WO-95/24414 (1995-09-01), None
patent: WO-95/24473 (1995-12-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/39515 (1996-12-01), None
patent: WO-97/00271 (1997-01-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-97/08320 (1997-03-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/17442 (1997-05-01), None
patent: WO-97/19694 (1997-06-01), None
patent: WO-98/06844 (1998-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/24811 (1998-06-01), None
patent: WO-98/33917 (1998-06-01), None
patent: WO-98/39035 (1998-09-01), None
patent: WO-98/49300 (1998-11-01), None
patent: WO-98/55619 (1998-12-01), None
patent: WO-98/56936 (1998-12-01), None
patent: WO-99/02545 (1999-01-01), None
patent: WO-99/08522 (1999-02-01), None
patent: WO-99/20749 (1999-04-01), None
patent: WO-99/21590 (1999-05-01), None
patent: WO-99/46364 (1999-09-01), None
patent: WO-00/73430 (2000-12-01), None
patent: WO-00/75163 (2000-12-01), None
patent: WO-01/57226 (2001-08-01), None
patent: WO-01/58956 (2001-08-01), None
patent: 9-403464 (1996-01-01), None
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79(6):1979-1983 (Mar. 1982).
Ngo et al., The Protein Folding Problem and Teriary Structure Prediction, pp. 492-495.
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4),” Proc. Natl. Acad. Sci. (USA), 95(2): 548-553 (1998).
Alderson, et al. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. Keystone Symposia, Ocular Cell and Molecular Biology, 202. (Abstract provided).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF,” J. Biol. Chem., 267(16): 11260-11266 (1992).
Andersson W.F., “Human gene therapy,”Science, 256:808-813 (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,” Cancer Research, 52:746-748 (1992).
Dignam et al., “Balbiani ring 3 inChironomus tentansencodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins,”Endocrine Rev. 13(l): 18-32 (1992).
Finnerty et al., “Molecular cloning of murine FLT and FLT4,”Oncogene8(11): 2293-2298 (1993).
Heldin et al., “Structure of platelet-derived growth factor: implications for functional properties,”Growth Factors8:245-252 (1993).
Eichmann et al., “Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors,”Development125(4): 743-752 (1998).
Pajusola et al., “FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines,”Cancer Research52:5738-5743 (1992).
Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen,”Science246:1306-1309 (1989).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114:521-532 (1992).
Bell et al., “Human epidermal growth factor precuror: cDNA sequence, expression in vitro and gene organization,”Nucl. Acids Res. 14(21): 8427-8446 (1986).
Berse et al., Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,Mol. Biol. Cell. 3:211-220 (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature320:695-699 (1986).
Claffey et al., “Vascular endothelial growth factor,”J. Biol. Chem. 267(23): 16317-16322 (1992).
Corson et al., “Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end,”Genomics17:476-484 (1993).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides,”J. Cellular Biochemistry47:211-218 (1991).
George et al., “Current Methods in Sequence Comparison and Analysis,” Macromolecular Seq. and Syn. Selected Meth—Application (Alan R. Liss), pp. 127-149 (1988).
Hu et al., “A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells,”FASEB J., 11:498-504 (1997).
Joukov et al., “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases,”EMBO J. 15(2): 290-298 (1996).
Joukov et al., “Proteolytic processing regulates receptor specificity and activity of VEGF-C,”EMBO J. 16(13): 3898-3911 (1997).
Kaipainen et al., “The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells,”J. Exp. Med. 178:2077-2088 (1993).
Keck et al., “Vascular permeability factor, an endothelial cell mitogen related to PDGF,”Science246: 1309 (1989).
Kingsley, D., “The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms,”Genes&Development8: 133-146 (1994).
Kukk et al., “VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development,”Development122: 3829-37 (1996).
Lee et al., “Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4,”Proc. Natl. Acad. Sci.(USA), 93:1988-1992 (1996).
Maglione et al., “Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14,”Oncogene8:925-931 (1993).
Maglione et al., “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor,”Proc. Natl. Acad. Sci.(USA), 88:9267-9271 (1991).
Massague, J., “The transforming growth factor-beta family,”Annu. Rev. Cell Biol. 6:597-641 (1990).
Matthews et al., “A receptor tyrosine kinase cDNA isolate

Affiliated with

Also associated with

Rating

Antibodies to vascular endothelial growth factor 2 (VEGF-2) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to vascular endothelial growth factor 2 (VEGF-2), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to vascular endothelial growth factor 2 (VEGF-2) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2769329